{"prompt": "['MCW', 'OUTPATIENT', 'CPX-351', 'TRIAL', 'TABLE OF CONTENTS', 'PROTOCOL SUMMARY', '7', 'STUDY SCHEMA', '9', 'STUDY CALENDAR OF EVENTS', '10', 'LIST OF ABBREVIATIONS', '13', '1 BACKGROUND AND RATIONALE', '15', '2 AIM AND ENDPOINTS', '17', '2.1 PRIMARY AIM', '17', '2.2 SECONDARY AIMS', '17', '2.3 PRIMARY ENDPOINTS', '17', '2.4 SECONDARY ENDPOINTS', '18', '3 STUDY DESIGN', '19', '3.1 GENERAL DESCRIPTION', '19', '3.2 DESIGN OF CURRENT STUDY', '19', '4 OPERATIONAL CRITERIA', '19', '4.1 SIRB REQUIREMENTS', '19', '4.2 SUBJECT STATUS', '19', '4.3 PRESCREENING LOG', '20', '4.4 CONSENT AND TRAINING', '20', '4.4.1 Nurse Teacher Education Program', '20', '4.4.2 Subject and Caregiver Consent', '21', '4.4.3 Study Diaries', '22', '4.4.4 Ongoing Consent Process and Education', '22', '4.5 SCREENING PROCEDURES.', '22', '4.6 CENTRAL ELIGIBILITY CONFIRMATION', '23', '4.7 ELIGIBILITY CRITERIA', '24', '4.8 ENROLLMENT', '27', '4.9 TREATMENT', '27', '4.10 DISCONTINUATION OF STUDY TREATMENT/INTERVENTION, WITHDRAWAL, AND', 'COMPLIANCE', '27', '4.11 FOLLOW-UP AND LOST TO FOLLOW-UP', '30', '4.12 ACCRUAL SUSPENSION AND CLOSURE', '30', '4.13 END OF STUDY DEFINITION', '31', '4.14 STUDY DISCONTINUATION AND CLOSURE', '31', '5 TREATMENT PLAN', '31', '5.1 DOSE MODIFICATION GUIDELINES', '32', '5.2 CONCOMITANT AND PROHIBITED MEDICATION', '32', '5.3 DIETARY RESTRICTIONS', '32', '5.4 SUPPORTIVE CARE GUIDELINES', '32', '5.4.1 Antimicrobial Prophylaxis', '32', '5.4.2 Myeloid Growth Factors', '33', '5.4.3 Indications for Hospitalization', '33', '5.4.4 Transfusion Support', '33', '5.5 OVERDOSE', '33', '5.6 CHANGES TO SITE OUTPATIENT MANAGEMENT CAPABILITIES', '34', 'MCW Protocol No: IIT-Michaelis-OutpatientCPX-35', 'p4', 'Version No.: 3', 'Version Date: 04/15/2020']['MCW', 'OUTPATIENT', 'CPX-351', 'TRIAL', '5.7 SUBJECT/CAREGIVER AND SITE COMMUNICATION PLAN', '34', '5.8 DEFINITION OF A PROTOCOL MANDATED APPOINTMENT', '34', '5.9 DEFINITION OF ADMISSION, PROVIDER RECOMMENDATION AND INPATIENT TIME', '34', '5.9.1 Subject Refusal to be Admitted', '35', '5.10 HEALTH-RELATED QUALITY OF LIFE QUESTIONNAIRES', '35', '6 REPORTING REQUIREMENTS', '37', '6.1 DEFINITION OF AN ADVERSE Event', '37', '6.2 DEFINITION OF A SERIOUS ADVERSE Event (SAE)', '37', '6.3 RELATIONSHIP OF AN ADVERSE EVENT TO STUDY', '37', '6.4 EXPECTEDNESS OF AN ADVERSE EVENT', '38', '6.5 ROUTINE AND EXPEDITED REPORTING', '38', '6.6 SERIOUS ADVERSE Event REPORTING', '39', '6.7 ADVERSE Events AND GRADE 4 AEs NOT MEETING SAE DEFINITION', '40', '6.8 UNANTICIPATED PROBLEM INVOLVING RISK TO SUBJECT OR OTHER (UPIRSO)', '41', '6.9 REPORTING PREGNANCY', '42', '6.10 PROTOCOL DEVIATIONS AND OVERDOSE', '42', '6.11 JAZZ PHARMACEUTICALS SAFETY LETTERS AND ACTION LETTERS', '43', '6.12 CHANGES TO OUTPATIENT MANAGEMENT CAPABILITIES', '44', '6.13 SUBJECT WITHDRAWAL', '44', '6.14 STAFF AND SUBJECT COMPLAINT REPORTING', '44', '6.15 REPORTING UPIRSO TO SUBJECTS', '44', '6.16 EXTERNAL OR INTERNAL AUDITING AT PARTICIPATING SITES', '44', '7 OPERATIONAL CONSIDERATIONS, MULTISITE ADMINISTRATION, SOURCE', 'DOCUMENTS, AND DATA MANAGEMENT', '45', '7.1 SITE STAFF OPERATIONS', '45', '7.1.1 Staff Roles', '45', '7.1.2 Training', '45', '7.1.3 Staff and Protocol Changes', '46', '7.1.4 Delegation of Authority Log', '47', '7.2 MONITORING PLAN', '47', '7.3 AUDIT PLAN', '48', '7.4 AUDIT AND MONITORING REPORT AND CORRECTIVE ACTION PLAN (CAP)', '48', '7.5 DEIDENTIFIED SOURCE DOCUMENTS, REMOTE ACCESS TO RECORDS, AND SHADOW CHARTS', '49', '7.6 TRANSFERRING SUBJECTS', '50', '7.7 DATA LOCK AND VERIFICATION', '50', '7.8 CLOSEOUT PROCEDURES AND RETENTION OF STUDY DOCUMENTS', '50', '7.9 STUDY RECORDS RETENTION', '51', '7.10 PUBLICATION AND DATA SHARING POLICY', '51', '7.11 ELECTRONIC DATA CAPTURE AND TIMELY DATA ENTRY', '51', '8 REGULATORY COMPLIANCE, ETHICS AND MANAGEMENT', '52', '8.1 PRESTUDY REQUIREMENTS FOR MCW', '52', '8.2 PARTICIPATING SITE ACTIVATION PROCESS', '52', '8.2.1 Participating Site Selection Criteria', '52', '8.2.2 Participating Site Feasibility Assessment', '53', '8.2.3 Activation Letter', '53', '8.3 REGULATORY REQUIREMENTS FOR MCW', '54', '8.4 REGULATORY RESPONSIBILITIES FOR PARTICIPATING SITES', '54', '8.5 SITE STANDARD OPERATING PROCEDURES (SOPS)', '54', 'MCW Protocol No:IIT-Michaelis-OutpatientCPX-351', 'p5', 'Version No.: 3', 'Version Date: 04/15/2020']\n\n###\n\n", "completion": "END"}